Endo Pulls Opioid as U.S. Seeks to Tackle Abuse Epidemic

Endo International Plc said on Thursday it agreed to withdraw its long-acting opioid painkiller Opana ER from the market after the U.S. Food and Drug Administration declared its benefit did not outweigh public health risks associated with opioid abuse.

Read more here.